Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Real World Study on the Effect of Single or Combined Treatment of Anlotinib on Survival and Prognosis of Advanced Esophageal Cancer

NCT04966611 is registered in ClinicalTrials.gov with Anyang Tumor Hospital as lead sponsor.

NCT NCT04966611
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04966611 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Real World Study on the Effect of Single or Combined Treatment of Anlotinib on Survival and Prognosis of Advanced Esophageal Cancer
Lead sponsor
Anyang Tumor Hospital
Phase
Observational
Overall status
Unknown status
Start date
July 15, 2021
Completion date
July 15, 2024
Enrollment
200 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer